% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • gizmo_puppy95 gizmo_puppy95 Apr 24, 2013 1:49 AM Flag

    A LOT of Institutional Buying

    In March, between Barclays, Blackrock and Vanguard we are talking close to 2 Million New shares owned. Bernstein bought over 1 million in March.
    This company is receiving a lot of LOVE!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It's no secret here why funds would be buying. Celldex is a huge value under 20/share. I think just about 20/share could be justified now without any additional news. Buying will likely slow at just under 20 (about 1.5BB market cap) unless there is additional news. With additional news on clinical and/or preclinical studies, additional institutional ownership as a percentage of total outstanding, partnership and/or breakthrough status on Rindo or CDX-011 we shoudl easily break that level and depending on the nature of the news settle in the mid-twenties until later in the year at ongoing work matures as we move towards becoming a comercial stage-biotech from a pure research-stage company.

      Sentiment: Strong Buy

    • When I see CLDX at Just 13 and change and I compare it to DNDN (which I owned) and watched it go into the 50s with one drug, Provenge, we are nowhere near where CLDX is heading imo

    • Over 9 Million shares were INCREASED in March.
      Ya Wonder why this has been on such a run?
      That is MAJOR buying...and there is NO reason to sell, other than securing profits. But it is very likely they will keep their core shares (owned in 2012).
      So I see this running much higher folks.
      When a stock just runs right past its 52 week high, that is a BULL signal.

      • 2 Replies to gizmo_puppy95
      • """Ya Wonder why this has been on such a run?"""

        May have something to do with the following:

        1. One drug in pivotal PIII, a second drug going into accelerated approval PIII in a couple of months, a third possibly going into accelerated approval PIII next year:
        - Rindo in pivotal PIII in GBM, trial powered to show a ~2 month survival benefit, will likely come in with a 4-5 month survival benefit- very high probability of success. EGFRvIII cancer marker which is target for Rindo recently reported to be a cancer stem cell marker- may explain why brain cancer pts who were expected to live

        Sentiment: Strong Buy

      • devineinstallationllc devineinstallationllc Apr 24, 2013 10:17 AM Flag

        hey guys, thanksi have aug $12 calls & i kinda just started trading options , have fair amount of stock trading experience..i bought the breakout @ 9.50 so i got pretty good gains. any suggestions on a strategy here?

6.74+0.29(+4.50%)Feb 11 4:00 PMEST